Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin

Journal of Viral Hepatitis

Volumn 19, Issue 11, 2012, Pages 766-774

  Zeuzem, Stefan ^a   Rodriguez Torres M ^b   Rajender Reddy, K ^c   Marcellin, P ^d   Diago, M ^e   Craxi, A ^f   Pockros, P ^g   Rizzetto, M ^h   Bernstein, D ⁱ   Shiffman, M L ^j   Lin, A ^k   Tatsch, F ^l   Hadziyannis, S ^m  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Fundación de Investigación de Diego   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d University of Paris   (France)

^e Hospital Clínic de València   (Spain)

^f UNIVERSITY OF PALERMO   (Italy)

^g SCRIPPS CLINIC   (United States)

^h MOLINETTE HOSPITAL   (Italy)

ⁱ Digestive Diseases Institute   (United States)

^j Bon Secours Health System   (United States)

^k HOFFMANN LA ROCHE INC   (United States)

^l F HOFFMANN LA ROCHE LTD   (Switzerland)

^m HENRY DUNANT HOSPITAL   (Greece)

more..

Author keywords

alanine aminotransferase; baseline predictor; HCV genotype 1; HCV viral load; sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; ROC CURVE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84867402011     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01624.x     Document Type: Article

References (29)

1. Dienstag JL, McHutchison JG,. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-264.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
3. Zeuzem S,. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370-381.
4. EASL consensus panel. EASL International Consensus Conference on Hepatitis C. Paris, 26-28 February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956-961.
5. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
6. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
7. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680.
8. Pockros PJ, Carithers R, Desmond P, et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004; 99: 1298-1305.
9. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
10. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
11. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
12. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
13. Scott JD, Gretch DR,. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA 2007; 297: 724-732.
14. Pegasys. Summary of product characteristics. Available at: http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/ 000395/WC500039196.pdf (accessed 20 September 2010).
15. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-1089.
16. Dalgard O, Bjøro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 35-42.
17. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-960.
18. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47: 43-50.
19. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-134.
20. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-1732.
21. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
22. Hastie T, Tibshirani R,. Generalized Additive Models. London: Chapman & Hall, 1990.
23. Dienstag JL, McHutchison JG,. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225-230.
24. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36 (s1): S3-S20.
25. Berg T, von Wagner M, Hinrichsen H, et al. Definition of a pre-treatment viral load cut-off for an optimized prediction of treatment outcome in patients with genotype 1 infection receiving either 48 or 72 weeks of peginterferon alfa-2a plus ribavirin. Hepatology 2006; 44 (s1): 321A.
26. Zehnter E, Mauss S, John C, et al. Better prediction of SVR in patients with HCV genotype 1 (G1) with peginterferon alfa-2a (PEGASYS) plus ribavirin: improving differentiation between low (LVL) and high baseline viral load (HVL). Hepatology 2006; 44 (s1): 328A.
27. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-1023.
28. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
29. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-624.